clinical trial · NCT07082842
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Sunshine Lake Pharma Co., Ltd.·phase3·recruiting·n = 472
Idiopathic Pulmonary Fibrosis (IPF)HEC585PlaceboPirfenidone
brief summary
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)
started
Oct 27, 2025
primary completion
Jan 15, 2031
completion
Feb 15, 2032
last updated
Apr 21, 2026
official title
A Multicenter, Parallel, Randomized, Placebo (Double-blind) and Pirfenidone (Open-label) Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HEC585 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol